ecember 29, 2007, the first day of its 2008 fiscal year.
Prior to the acquisition, the Company reported its 50% ownership interest
in STAAR Japan as an equity investment and did not incorporate STAAR
Japan's financial data in the Company's financial statements. As a result,
the Company's financial results in 2008 have been significantly affected by
both non- recurring charges resulting from the accounting treatment of the
transaction and by the consolidation of the results of STAAR Japan from the
first quarter of 2008 forward. STAAR's management believes that it is
important for investors to be able to identify the trends in its core
business, including expense reduction, revenue enhancement and gross profit
improvement, and that these trends can be discerned only by a comparison of
2007 financial data with non-GAAP 2008 data that excludes the newly added
results from STAAR Japan. Since acquisition of the remaining interests in
STAAR Japan, the Company's management has used this non-GAAP information
internally to measure its progress compared to 2007 in achieving positive
cash flow and returning to profitability. The Company's management
currently believes that this information will enhance investors' overall
understanding of its core performance when financial statements include
comparisons to periods preceding the STAAR Japan acquisition. Going
forward, the Company must achieve positive cash flow and profitability as a
consolidated enterprise with STAAR Japan, and accordingly the Company
cautions investors to consider both the GAAP financial statements as well
as the non-GAAP financial information.
(Tables to Follow)
STAAR Surgical Company
Condensed Consolidated Statements of Income
(In 000's except for per share data)
Unaudited
Three Months Ended Nine Months Ended
September September September September
'/>"/>
SOURCE STAAR Surgical Company Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Related medicine news :1.
STAAR Surgical to Present at the Noble Financial Equity Conference2.
STAAR Surgicals Collamer(R) IOL and Elastimide(R) IOL Each Recognized with New Technology Intraocular Lens Classification3.
STAAR Surgicals LASIK Alternative Expands U.S. Market Gains4.
STAAR Surgical Reports Solid First Quarter Progress5.
STAAR Surgical Announces First Quarter 2008 Earnings Release Date and Conference Call6.
STAAR Surgical Plans Major Presence at ASCRS7.
STAAR Surgical Reports Fourth Quarter and Year End Results8.
STAAR Surgicals Visian ICL Procedure Performed Live on NBCs Today show9.
STAAR Surgical Announces Fourth Quarter and Full Year 2007 Earnings Release Date and Conference Call10.
STAAR Surgical to Present at the Tenth Annual Needham Growth Conference11.
STAAR Surgical Completes $5M Debt Financing for Purchase of Japanese Joint Venture